Search Results for “cancer” – Page 112 – media

MIT study reveals why certain immunotherapies do not always work

A new Massachusetts Institute of Technology (MIT) study has revealed a potential explanation as to why certain immunotherapies for cancerous tumours do not always work as predicted. If validated in clinical trials, the findings could help doctors identify cancer patients who would benefit the most from drugs known as checkpoint blockade inhibitors. Checkpoint blockade inhibitors work by stimulating immune cells to destroy tumours in the body’s T cell response. In previous studies, findings have shown that these drugs work effectively in patients whose tumours have a large number of mutated proteins. However, 50% of patients who received the US Food and Drug Administration-approved checkpoint blockade inhibitor, pembrolizumab, did not respond well or only showed short-lived responses, despite their tumours showing high mutational burden. In a study of mice, the researchers revealed that measuring the diversity of mutations within a tumour generated a more accurate prediction as to whether immunotherapy treatment ...
- Source: drugdu
- 105
- October 1, 2023
Genentech, PeptiDream Ink Potential $1B Radiopharma Deal

By Kate Goodwin Pictured: Businessmen shaking hands/iStock, Tippapatt Japanese biopharma PeptiDream on Wednesday announced yet another licensing agreement with Roche’s Genentech, this time worth up to $1 billion. The latest deal builds on previous partnerships between the two companies starting in December 2015 with licensing in 2016 and an expansion deal in 2018. PeptiDream will receive $40 million upfront for R&D of its macrocyclic peptide-radioisotope drug conjugates. Going forward, another $1 billion is on the line in milestones plus tiered royalties of product sales to markets outside of Japan. PeptiDream will oversee preclinical activities to develop a peptide-RI drug conjugate and retain rights in Japan for any products developed. While a particular target was not disclosed, PeptiDream CEO Patrick Reid said in a statement that the company hopes to “bring innovative first-in-class peptide radiopharmaceuticals to patients worldwide.” The peptide-RI drug conjugates in the deal with Genentech are designed to use ...
- Source: drugdu
- 114
- September 30, 2023
Meitheal partners with Chinese company for US licencing of insulin biosimilars

Meitheal Pharmaceuticals has signed an exclusive licensing agreement with the China-based Tonghua Dongbao Pharmaceutical to commercialise three insulin biosimilars in the US. The insulin biosimilars include two rapid-acting insulins, namely insulin lispro and insulin aspart, and the long-acting insulin glargine. The rights were acquired by Meitheal’s parent company Nanjing King-Friend Biochemical Pharmaceutical. Eli Lilly reported global sales of $440.4m for the branded version of insulin lispro Humalog in n Q2 2023, while Sanofi’s Lantus (insulin glargine) had global sales of $353m in the same period, as per the company’s Q2 financials. Meitheal will have exclusive US marketing rights after the insulin biosimilars are approved by the US Food and Drug Administration (FDA), which is expected in 2026. As part of the agreement, both Tonghua Dongbao and Nanjing King-Friend Biochemical would be responsible for the development and supply of all three insulin biosimilars. All three companies will also share the royalties ...
- Source: drugdu
- 94
- September 30, 2023
Oxford Biodynamics launches prostate screening test

EpiSwitch is designed for men with prostate cancer risk in the UK and is 94% accurate Oxford BioDynamics – a company developing precision medicine tests – has announced that its EpiSwitch Prostate Screening (PSE) blood test will be available to UK patients. The existing PSA test is 55% accurate, and is considered an unreliable test by many doctors, including those in the NHS. The new PSE test has been designed to run alongside the standard PSA test, and combines the PSA score with five proprietary epigenetic biomarkers to predict – with 94% accuracy – the presence (or absence) of prostate cancer. The PSE test has emerged after nearly a decade’s long collaboration between OBD, Imperial College London, University of East Anglia, Imperial College NHS Trust and leading prostate cancer experts across the UK. The development was also part of the wider PROSTAGRAM screening pilot. Mathias Winkler, Consultant Urologist and Surgeon ...
- Source: drugdu
- 114
- September 29, 2023
As chemotherapy shortage ebbs and flows, attention shifts to long-term solutions

It’s been about 10 months since FDA inspectors rebuked a production plant in India that made popular platinum-based chemotherapies, kicking off a chain reaction of drug shortages that continues to jeopardize cancer care in the U.S.While the White House recently announced that overseas importations and other efforts have increased U.S. supplies of carboplatin and cisplatin, not all clinics are able to access the drugs, according to the American Society of Clinical Oncology’s (ASCO’s) chief medical officer Julie Gralow, M.D. Even as supplies recover around the country, a “certain set” of cancer clinics are still unable to get their hands on the medicines, Gralow said in an interview. The disparity in availability reflects the disproportionate impact the shortage has had on patients based on factors such as location or socioeconomic status, Gralow added. It’s often smaller sites that can’t secure the drugs. While bigger hospitals may have them, those sites often ...
- Source: drugdu
- 152
- September 29, 2023
Siemens Healthineers buys Aspekt to bolster radiation oncology services

Dive Brief Siemens Healthineers has acquired Aspekt Solutions to strengthen the service offering at its Varian cancer therapy unit. Neither party disclosed the value of the deal. Aspekt supports radiation oncology sites — the type of health centers that use Varian devices — with services such as dosimetry consulting, clinic management, technology evaluation and staffing. Varian sees the acquisition as complementary to its Advanced Oncology Solutions unit, which provides professional and clinical services to improve the implementation of its technologies. Dive Insight Varian, a provider of radiation oncology equipment and software, pitches its AOS unit as enabling sites to adopt technologies, improve quality and expand capacity. The unit collaborates with radiation oncology sites to simplify data entry, optimize databases, reduce variation between dosimetrists and train staff on safety. In doing so, Varian aims to address challenges such as the rising cost of care and staff shortages. “Through our AOS offerings, ...
- Source: drugdu
- 99
- September 29, 2023
AbbVie Ends I-Mab Deal for CD47 Antibody Compounds, Products

By Tristan Manalac Pictured: AbbVie headquarters in California/iStock, Michael Vi AbbVie has terminated its license and collaboration agreement with I-Mab, the Maryland- and Shanghai-based biotech announced in an SEC filing posted Friday. As a result, I-Mab will regain the global rights to develop and commercialize all CD47 compounds covered by the deal, including the monoclonal antibody lemzoparlimab. The termination will take effect on Nov. 20, 2023 and will not affect the $200 million in upfront and milestone payments that I-Mab had already received from AbbVie. According to I-Mab’s SEC document, AbbVie is pulling away from the partnership as a “strategic decision,” though a prior program discontinuation also factored into its decision. AbbVie and I-Mab first entered into their global agreement in September 2020. For an upfront payment of $180 million and the promise of up to $1.74 billion in success-based milestones, AbbVie earned exclusive rights—outside of the greater China area—to ...
- Source: drugdu
- 174
- September 27, 2023
Kinnate Biopharma announces 70% layoffs and pipeline restructuring

Kinnate Biopharma plans to sack around 70% of its workforce and stop the development of three programmes as a result of its strategic review. The company expects to retain 28 full-time employees after the layoffs are concluded, per the 18 September press release. The US-based oncology company has also decided to consider strategic alternatives for the exarafenib monotherapy programme and the asset KIN-3248, which is designed for use in cancers with FGFR2 and FGFR3 alterations. Despite the clearing of KIN-7136’s investigational new drug application (IND), Kinnate will also not be going ahead with its Phase I trial. The strategic review reflects multiple factors that include its cash runway and the commercial potential of its programmes, based on the 18 September update. Although exarafenib was well tolerated by patients in a Phase I trial (NCT04913285), it displayed limited anti-tumour activity in subjects with Class II alterations. The company has decided to ...
- Source: drugdu
- 104
- September 21, 2023
FDA Approves GSK’s Momelotinib for Myelofibrosis Patients with Anemia

By Tristan Manalac Pictured: GSK building in Poland/iStock, Wirestock The FDA on Friday approved GSK’s oral drug momelotinib, now to be marketed under the brand name Ojjaara, for the treatment of myelofibrosis in adults with anemia. Myelofibrosis patients often develop anemia, which forces them to discontinue treatment and raise the need for transfusions. Ojjaara’s approval will help address this “significant medical need in the community” and lead to better outcomes in these patients, Nina Mojas, GSK senior vice president for oncology global product strategy, said in a statement. With Friday’s approval, Ojjaara becomes the first authorized treatment for both newly diagnosed and previously treated myelofibrosis patients with anemia that also targets the key symptoms of the condition, according to the company’s press release. The approval comes after a three-month delay in June 2023, which the FDA said was to give it more time to review additional data supporting the application. ...
- Source: drugdu
- 211
- September 20, 2023
Anthos Stops Mid-Stage Atrial Fibrillation Trial Due to ‘Unprecedented’ Efficacy

By Tristan Manalac Pictured: Illustration of a blood clot in a blood vessel/iStock, libre de droit Anthos Therapeutics is ending the Phase II AZALEA-TIMI 71 study ahead of schedule after its investigational monoclonal antibody abelacimab demonstrated an “overwhelming reduction” in bleeding compared to Bayer and Johnson & Johnson’s Xarelto (rivaroxaban), the company announced Monday. Patients treated with abelacimab saw a sharp reduction in the composite endpoint of major and clinically relevant non-major bleeding events compared with counterparts given rivaroxaban, the current standard-of-care oral anticoagulant. The Massachusetts-based biopharma did not provide specific data in Monday’s announcement but said that the Data Monitoring Committee stopped the study early following these data. Anthos will share the full results and analysis of the trial in an upcoming medical meeting. Due to the “overwhelming reduction in bleeding” reported in AZALEA-TIMI 71, abelacimab may represent a “paradigm shift” in atrial fibrillation care particularly in the prevention ...
- Source: drugdu
- 95
- September 20, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.